- Open Access
Epigenetic approaches in stem cell transplantation
© Springer-Verlag 2011
- Received: 28 April 2011
- Accepted: 28 June 2011
- Published: 16 July 2011
- Natural Killer Cell
- HDAC Inhibitor
- Acute GvHD
The terms ‘haematopoietic stem cell’ and ‘stem cell transplantation’ have been defined by Little and Storb (2002): “A primitive and immature cell of the haematopoietic system that has the capacity to give rise to all the cells of the blood system, as well as the ability to self-renew. Allogeneic haematopoietic stem cell transplantation involves the transfer of both immature and mature blood cells from the bone marrow, peripheral blood or cord blood from one individual to another.” The first experiences in haematopoietic transplantation have been made in mice in the late 1940s and the early 1950s by Jacobson et al. (1949) and Lorenz et al. (1951) in the wake of the first atomic bomb explosions in Japan and its life-threatening effects due to bone marrow failure. Since then, every decade is featured by revolutionary developments. Epigenetic approaches might be the discovery of the 2010s.
Indications for allogeneic haematopoietic transplantation are both malignant and nonmalignant diseases; most of all transplantations are administered for haematological malignancies, e.g. acute and chronic leukaemias, myelodysplasia and myeloproliferative disorders.
Procedure of allogeneic stem cell transplantation: main phases and principles
1 Conditioning regimen
a) Cytoreductive chemotherapy
Reduction of tumour burden
Induction of remission
Elimination of the immune system of the recipient by (high-dose) chemotherapy or irradiation
2 Stem cell transfusion
Donation of “the new” immunosystem
Prevention and treatment of graft rejection and graft-versus-host disease
4 Alloreactivity as further medicinal intervention: maintenance and relapse therapy
Elimination of residual malignant cells by the graft-versus-leukaemia reaction, enhancement of the immunotherapeutic effect by donor lymphocyte infusions
Pathogenesis of acute GvHD is explained by the three-phase model proposed by Ferrara et al. (2009). At first, tissue damage caused by high-dose chemotherapy and irradiation (conditioning regimen) induces translocation of bacterial products (lipopolysaccharides) through gut mucosa or skin leakage and stimulates proinflammatory cytokine release: interleukin (IL)-1, IL-6 and tumour necrosis factor alpha (TNF-α). Thus, host antigen-presenting cells (APCs) are activated and migrate into secondary lymphoid organs. In the second phase, activated host APCs induce proliferation and cytokine production (IL-2 and interferon gamma, INF-γ) of donor T lymphocytes by presenting alloantigens. Furthermore, donor T cells differentiate into alloreactive effector T cells against different alloantigens (minor histocompatibility antigens). In the last step, two important components mediate inflammation: cellular effectors like activated alloreactive effector T cells and natural killer (NK) cells on the one hand and soluble inflammatory cytokines as TNF-α, IFN-γ and IL-1 on the other hand. This in turn causes target cell apoptosis and thereby enhances alloantigen presentation as well as cytokine release, thus amplifying and sustaining the inflammatory reaction.
Acute GvHD occurring within the first months after transplantation must be differentiated from chronic GvHD, whose pathophysiology still remains unclear. Depending on organ involvement, patients with acute GvHD suffer from skin rash up to blisters and ulcers, severe diarrhoea and wasting syndrome or elevated liver enzymes up to liver failure.
However, alloreactive T cells do not only recognize solid organ tissue like skin, gut and liver, but also residual malignant cells. This favourable effect named graft-versus-leukaemia reaction has been observed especially in myeloid leukaemias (Kolb 2008) and is the great benefit of allogeneic transplantation. Therefore, the intention is prevention and treatment of GvHD while preserving GvL.
With regard to epigenetic targets, there are two important cellular mechanisms: regulatory T cells suppress GvHD without altering GvL, and NK cells and killer cell immunoglobulin-like receptors enhance GvL without inducing GvHD.
Regulatory T cells—maintenance of (self-) tolerance
Regulatory T cells (Tregs) are known to regulate inflammatory response and suppress alloreactive T cells; the exact mechanism is unknown so far. They suppress autoimmunity and GvHD without decreasing GvL (Edinger et al. 2003). Mice deficient for Tregs usually suffer from autoimmune diseases, and even in humans, autoimmune disorders are often accompanied with Tregs dysfunction, e.g. Forkhead transcription factor Foxp3 gene mutation (Fontenot et al. 2003; Bennett et al. 2001). Recent data suggest that FOXP3 is necessary and essential for sufficient and functional Tregs that are defined as CD4+CD25+FOXP3+ T cells. The Foxp3 locus is regulated by epigenetic modifications like acetylation and methylation (Floess et al. 2007; Tao et al. 2007) and is unmethylated in active Tregs. Regulatory T cells CD4+CD25+FOXP3+ are mainly generated in the thymus, but may also arise from naïve CD4+CD25− T cells in the periphery by T cell-receptor stimulation. The number of circulating Tregs in vivo is low, and purification methods in vitro still remain inefficient. The ambitious attempt of in vitro expansion of Tregs also failed so far because of loss of suppressor function of expanded Tregs possibly due to inactive Foxp3 (Oliveira et al. 2008). As reported by Floess et al. (2007) and Tao et al. (2007), FOXP3 expression must be stabilized by epigenetic modifications such as complete demethylation of a highly conserved region within the noncoding region of FOX3 and acetylation of lysine residues in the forkhead domain by inhibition of HDACs.
Natural killer cells: KIR expression and alloreactivity
NK cells have been shown to have alloreactive potential in the donor–recipient direction and induce tumour cell lysis without immune sensitization of the recipient before (Colonna et al. 1993; Ciccone et al. 1992; Kiessling et al. 1975). As recently reviewed by Pegram et al. (2011), NK cell activity is regulated by inhibitory and activating killer cell immunoglobulin-like receptors (KIR) whose ligands are major histocompatibility complex (MHC) class I molecules. If MHC class I ligands for inhibitory KIR are missing on target cells, NK cells are activated and mediate cell lysis with preference against tumour cells. That implies reaction against leukaemia (GvL) without GvHD. There is evidence that enhanced KIR mismatch in haploidentical transplantation setting is followed by an intensified immunological reaction and boosts graft versus leukaemia effect (Apperley et al. 2008; Ruggeri et al. 2002; Pende et al. 2005).
Epigenetic agents prior to HSCT
Low disease burden prior to haematopoietic transplantation is known to come along with favourable outcome and reduced relapse incidence, although treatment-related mortality is increased by pretransplant induction chemotherapy. The beneficial antileukaemic effect of epigenetic active drugs by activation of silenced genes, derepression of tumour suppressor genes and induction of differentiation can be used by adding DNMT and HDAC inhibitors to the conditioning regimen or cytoreductive chemotherapy.
DNMT inhibitors: decitabine and 5-azacytidine
Epigenetic agents prior to HSCT (allogeneic haematopoietic transplantation)
Outcome after HSCT
[median] Follow-up (months)
40% CR, 10% PR
33% relapse, 33% alive
(Lubbert et al. 2006)
De Padua 2007
33% CR, 50% PR
17% relapse, 75% alive
(De Padua Silva et al. 2007)
(McCarty et al. 2008)
de Lima 2003
12× AML, 1xCMML, 1× ALL, 9× CML
39% relapse, 26% alive
(de Lima et al. 2003)
3× CML, 1× AMML
(Giralt et al. 1997)
Epigenetic agents as immunomodulatory therapy
As mentioned above, the clinical goal of stem cell transplantation is reduction of GvHD while preserving GvL. Key mechanisms in the treatment of GvHD without altering GvL effect are regulation of cytokine levels, the interfering function of regulatory T cells (Tregs) and the important role of natural killer (NK) cells.
Promising preclinical data demonstrate the potent immunomodulatory effect of both HDAC and DNMT inhibitors in the treatment of GvHD without reducing the beneficial effect of GvL.
Regulation of cytokine level
Proinflammatory cytokines like TNF-α, IFN-γ, IL-1, IL-6 and IL-12 are essential mediators of GvHD sustaining the vicious circle of inflammation. HDAC inhibitor vorinostat (SAHA) has been shown to inhibit the production of proinflammatory cytokines TNF-α, IFN-γ, IL-1β and IL-12 in lipopolysaccharide-stimulated human peripheral blood mononuclear cells in vitro (Leoni et al. 2002). In bone marrow transplantation mouse model, addition of SAHA day +3 to +7 after transplantation prevents gastrointestinal tract damage by reducing cytokine release of TNF-α, IFN-γ and IL-1 in a dose-dependent manner. When compared with allogeneic controls, mortality and grade of acute GvHD were reduced corresponding to significantly improved survival (Reddy et al. 2004). Surprisingly, prophylactic treatment with SAHA did not alter cytotoxic T cell reaction against host antigens and thereby preserved GvL effect.
Epigenetic agents boost regulatory T cells (Tregs)
CD4+CD25+FOXP3+ Tregs are suppressors of autoimmunity and GvHD but do not reduce GvL effect; the exact mechanism is still not known. The circulating number of functional Tregs in vivo is limited and effective in vitro expansion, and purification methods are not available so far. DNMT inhibitors decitabine and 5-azacytidine as well as HDAC inhibitors have been reported to be potential stimulators of Tregs by inducing Foxp3 expression in CD4+CD25+FOXP3− T cells. Foxp3 is regulated by methylation and acetylation and is highly hypermethylated in nonfunctional Tregs. Treatment of mice with decitabine and 5-azacytidine after bone marrow transplantation expands Tregs, enhances the circulating number of functional Tregs by expression of Foxp3 and thereby limits GvHD without sacrificing GvL (Sanchez-Abarca et al. 2010; Choi et al. 2010). Application of HDAC inhibitors (trichostatin A, valproic acid and butyrate) in mice provides similar results (Tao et al. 2007).
DNMT inhibitors and natural killer cells
DNMT inhibitors as relapse therapy and maintenance after HSCT
Patients with leukaemic relapse after stem cell transplantation have a very poor prognosis, and treatment options are limited because of accumulated toxicity and impaired organ function. DNMT inhibitors decitabine and 5-azacytidine have been shown to be effective antileukaemic agents with acceptable toxicity profile that can be used safely in relapsed situation after HSCT (Giralt et al. 1997; Ravandi et al. 2001; Jabbour et al. 2009) (Table 3). Treatment with 5-azacytidine might even enhance GvL effect especially in combination with donor lymphocyte infusions as reported by Czibere et al. (2006). Furthermore, maintenance therapy with 5-azacytidine after stem cell transplantation might induce durable remission without increasing acute GvHD (Jabbour et al. 2009; de Lima et al. 2007; Table 4).
Epigenetic agents as relapse therapy after haematopoietic transplantation (HSCT)
2× AML, 1× ALL
1× relapse, 1× alive
(Giralt et al. 1997)
Dec + HSCT
9× AML, 2× ALL, 3× CML
5× relapse, 5x alive
(Ravandi et al. 2001)
1× relapse, 7× alive
(Jabbour et al. 2009)
5-Aza + DLI
3× CR, 2× PR
2× relapse, 2× alive
(Czibere et al. 2006)
5-Azacytidine (5-Aza) as maintenance therapy after haematopoietic transplantation (HSCT)
Recent clinical and preclinical data suggest the use of epigenetic active drugs as a promising new approach in stem cell transplantation in the 2010s. DNMT and HDAC inhibitors show high antitumour activity when both used as additional agents in conditioning regimen and as maintenance therapy or even for remission induction in relapsed situation after transplantation. When used in heavily pretreated patients, the favourable toxicity profile indicates safety and limited short-term side effects. Long-term side effects are not known so far. With respect to their impact on expression pattern of a wide range of genes and functionality of proteins, DNMT and HDAC inhibitors might interfere with different biological mechanisms. Induction of immunotolerance and anti-inflammation might even cause higher incidence of malignancies after long-term treatment. Furthermore, reduction of immune response might be supposed to result in an increased risk for opportunistic and other infections. Further studies are mandatory to evaluate the potential and safety of epigenetic agents in a higher number of cases.
Preclinical data indicate a beneficial immunomodulatory effect of DNMT and HDAC inhibitors by enhancing functional Tregs, regulating inflammatory cytokines and inducing GvL effect by enhancing KIR expression and variability of NK cells. Clinical data are still missing so far, and clinical studies should be investigated to verify the use of HDAC and DNMT inhibitors for GvHD prophylaxis and therapy.
Conflict of interest
The authors declare that they have no conflict of interest.
- Apperley J et al (2008) The EBMT handbook: haematopoietic stem cell transplantation. European Sch of Haematology 5:66–75Google Scholar
- Bennett CL et al (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27(1):20–21PubMedView ArticleGoogle Scholar
- Chan HW et al (2003) DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 197(2):245–255PubMedPubMed CentralView ArticleGoogle Scholar
- Choi J et al (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116(1):129–139PubMedPubMed CentralView ArticleGoogle Scholar
- Ciccone E et al (1992) Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 175(3):709–718PubMedView ArticleGoogle Scholar
- Colonna M et al (1993) Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 260(5111):1121–1124PubMedView ArticleGoogle Scholar
- Czibere A et al (2006) 5-Azacitidine in combination with donor lymphocyte infusions for the treatment of patients with MDS or AML relapsing after allogeneic stem cell transplantation. ASH Annual Meeting Abstracts108(11): 5341Google Scholar
- de Lima M et al (2003) Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97(5):1242–1247PubMedView ArticleGoogle Scholar
- de Lima M et al (2007) A dose and schedule finding study of maintenance therapy with low-dose 5-azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk AML or MDS. ASH Annual Meeting Abstracts 110(11): 3012Google Scholar
- De Padua Silva L et al (2007) Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2'-deoxy-5 azacytidine for patients with myelodysplastic syndrome. ASH Annual Meeting Abstracts 110(11): 1468Google Scholar
- Edinger M et al (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9(9):1144–1150PubMedView ArticleGoogle Scholar
- Ferrara JL et al (2009) Graft-versus-host disease. Lancet 373(9674):1550–1561PubMedPubMed CentralView ArticleGoogle Scholar
- Floess S et al (2007) Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 5(2):e38PubMedPubMed CentralView ArticleGoogle Scholar
- Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4(4):330–336PubMedView ArticleGoogle Scholar
- Fontenot JD et al (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22(3):329–341PubMedView ArticleGoogle Scholar
- Giralt S et al (1997) Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 11(Suppl 1):S32–S34PubMedGoogle Scholar
- Jabbour E et al (2009) Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899–1905PubMedPubMed CentralView ArticleGoogle Scholar
- Jacobson LO, Marks EK, Robson MJ, Gaston EO, Zirkle RE (1949) Effect of spleen protection on mortality following x-irradiation. J Lab Clin Med 34:1538–1543Google Scholar
- Kiessling R, Klein E, Wigzell H (1975) “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5(2):112–117PubMedView ArticleGoogle Scholar
- Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371–4383PubMedView ArticleGoogle Scholar
- Leoni F et al (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99(5):2995–3000PubMedPubMed CentralView ArticleGoogle Scholar
- Little MT, Storb R (2002) History of haematopoietic stem-cell transplantation. Nat Rev Cancer 2(3):231–238PubMedView ArticleGoogle Scholar
- Lorenz E et al (1951) Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 12(1):197–201PubMedGoogle Scholar
- Lubbert M et al (2006) Non-intensive AML/MDS treatment with low-dose decitabine prior to reduced-intensity conditioning (RIC) and allogeneic blood stem cell transplantation of older patients. ASH Annual Meeting Abstracts 108(11)):5257Google Scholar
- McCarty J et al (2008) 5-Azacytidine prior to allogeneic transplantation effectively reduces relapse, TRM and overall mortality in high risk myelodysplasia and secondary AML [Abstract]. Bone Marrow Transplant 41(S1):S212–S213Google Scholar
- Oliveira V et al (2008) Anti-CD4-mediated selection of Treg in vitro—in vitro suppression does not predict in vivo capacity to prevent graft rejection. Eur J Immunol 38(6):1677–1688PubMedPubMed CentralView ArticleGoogle Scholar
- Pegram HJ et al (2011) Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leuk Res 35(1):14–21PubMedView ArticleGoogle Scholar
- Pende D et al (2005) Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105(5):2066–2073PubMedView ArticleGoogle Scholar
- Ravandi F et al (2001) Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27(12):1221–1225PubMedView ArticleGoogle Scholar
- Reddy P et al (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101(11):3921–3926PubMedPubMed CentralView ArticleGoogle Scholar
- Ruggeri L et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100PubMedView ArticleGoogle Scholar
- Sanchez-Abarca LI et al (2010) Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 115(1):107–121PubMedView ArticleGoogle Scholar
- Tao R et al (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13(11):1299–1307PubMedView ArticleGoogle Scholar
- Wang X et al (2010) Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood 116(26):5972–5982PubMedPubMed CentralView ArticleGoogle Scholar